Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) CEO Michael Kauffman sold 20,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $41.76, for a total transaction of $835,200.00. Following the completion of the sale, the chief executive officer now directly owns 687,596 shares of the company’s stock, valued at approximately $28,714,009. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 0.26% during mid-day trading on Thursday, hitting $42.59. The stock had a trading volume of 337,670 shares. Karyopharm Therapeutics has a 52-week low of $15.50 and a 52-week high of $47.98. The stock’s 50-day moving average is $28.81 and its 200-day moving average is $29.98. The company’s market cap is $1.268 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.01. Analysts expect that Karyopharm Therapeutics will post $-2.03 EPS for the current fiscal year.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.